Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Inc.

中國醫療集團有限公司 (Carrying on business in Hong Kong as "萬全醫療集團")

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 08225)

CHANGE OF DIRECTORS AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

Resignation of Director

The Board of China Health Group Inc. (the "Company") hereby announces that Mr. QIU Rui ("Mr. Qiu") has tendered his resignation as an independent non-executive Director of the Company due to the work reasons, effective 5 February, 2024.

Mr. Qiu has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation as an independent non-executive Director that needs to be brought to the attention of the shareholders of the Company and of Hong Kong Limited (the "Stock Exchange").

The Board of the Company would like to express its gratitude to Mr. Qiu for his valuable contribution to the Company during his tenure of office.

Appointment of Directors

The Board of the Company further announces that Mr. WU Shuangsi ("Mr. Wu") has been appointed as an independent non-executive Director of the Company and Dr. WANG Dajun Denis ("Dr. Wang) has been appointed as an non-executive director of the Company in charge of corporate strategy and business development, with effect from 5 February 2024.

The curricula vitae of Mr. Wu and Dr. Wang are set out below:

Mr.Wu, 59, obtained a Master's degree in Business Administration (Finance and Economics) from the School of Business of the University of Hawaii in 1992, and his undergraduate degree is a first bachelor's degree from Tsinghua University and a second bachelor's degree from the University of Hawaii. Currently, he is the chairman of the supervisory board of Tianjin Warm Current Enterprise Management Consulting Co., the Chairman of the Board of Directors of China Sports Training (Beijing) Sports Development Company Limited, and the chairman of China Sports Training National Youth Sports Club (public welfare organization).

Dr. Wang, 58, obtained a master's degree in molecular biology from the Chinese Academy of Sciences (Beijing) in 1987, a Ph.D. in molecular medical genetics from the University of Toronto (Canada) in 1995, and an international MBA in international finance from International University of Japan (Japan) in 1998, Currently, he serves as a senior partner of Efung Capital (Shenzhen), a member of the investment committee of ASB Ventures, and a member of the monoclonal antibody professional committee of the China Medicinal Biotechnology Association, a financial advisor to the Jilin Provincial Government, a visiting professor of Changchun Normal University, and a visiting professor of Changchun Sci-Tec College.

Save as disclosed in this announcement, as at the date of this announcement, Mr. Wu and Dr. Wang:

(i)did not hold any position in the Company or other members of the Group;

(ii)did not hold any directorship in any public companies, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years preceding the date of this announcement;

(iii)were not interested in and did not have any interest in any shares or underlying shares or any debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong); and

(iv)were not connected and had no relationship with any Directors, senior management, substantial shareholders of the Company (as defined in the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the ''GEM Listing Rules'') or controlling shareholders of the Company (as defined in the GEM Listing Rules).

Save as disclosed in this announcement, the Board is not aware of other information to be disclosed pursuant to the requirements of Rule 17.50(2) of the GEM Listing Rules and there are no other matters relating to the appointment of Mr. Wu and Dr. Wang that need to be brought to the attention of the Shareholders.

Change in the Composition of Board Committees

The Board further announces that Mr. WU will be appointed as the Chairman of the Audit Committee, a member of the Remuneration Committee of the Board and a member of the Nomination Committee of the Board with effect from 5 February,2024

The Board warmly welcome Mr. Wu and Dr. Wang to join the Board.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board China Health Group Inc. GUO Xia Chairman

Hong Kong, 5 February 2024

As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia, Dr. SONG Xuemei; two non-executive Director, being Dr. ZHANG Li and Dr. WANG Dajun Denis; and three independent non-executive Directors, being Mr. WU Shuangsi, Dr. NI Binhui and Dr. GUO Tong.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for 7 days from the date of its posting. This announcement will also be posted on the Company's website at http://www.chgi.net.